Sulphasalazine Prevents Fibrosis; Relevance of TGFβRI
Elsayed Gomaa Elsayed Elsakka, Gamil Mohammed Abd-Allah, Ahmed Ibrahim Abulsoud, Ahmed Mohammed Ibrahim Mansour, Sayed Abdel Raheem
International Journal of Biochemistry Research & Review · pp. 1–10 · Published 10 Jun 2016
10.9734/IJBCRR/2016/25627Abstract
Aims: The aim of this study is to investigate the protective effect of sulphasalazine on liver fibrosis. Besides; investigation of the expression pattern of transforming growth factor β receptor I (TGFβRI) in liver fibrosis and the possible modulatory effect of sulphasalazine on it. Study Design: Controlled experiment. Place and Duration of Study: Department of Biochemistry and Department of Pharmacology and Toxicology, Faculty of pharmacy (boys) Al-Azhar University, between February 2015 and June 2015. Methodology: Five Sprague-Dawley rats groups were used for the experiment. Control group: Receiving corn oil; DMSO group: Injected with DMSO; 6 weeks group: Injected with 50% CCl4 in corn oil; sulphasalazine group: Injected with sulphasalazine and CCl4 and finally mesalazine group: were given mesalazine and CCl4. On the day after the last dose, rats were anesthetized with diethyl ether and blood samples were collected for measurement of blood chemistry. The animals then were euthanized, and livers were harvested and divided into 2 parts; one part was processed for standard histology and immunofluorescence techniques and the other was homogenized for oxidative status assessment. Results: TGFβRI has been shown to be upregulated in chronic liver injury; fibrosis stage; with expression occurring mainly in cell membrane of lesion area. This expression was decreased significantly with sulphasalazine treatment. Sulphasalazine has shown to have ability to diminish fibrosis in chronic liver injury. This decrease in fibrosis observed with sulphasalazine was in parallel with decrease in TGFβRI expression. Besides; this action of sulphasalazine has been suggested to be due to the whole molecule not to its moiety; mesalazine. Conclusion: TGFβRI may be used as a candidate marker for diagnosis and prognosis of chronic liver diseases. Besides; it may be used as a target therapy for chronic liver diseases. Moreover; sulphasalazine might be a promising adjuvant therapy for chronic liver diseases.
Cited by 0
No indexed citations yet.
Related research
- A Case Report on Management and Treatment of a Male Patient Suffering from Interstitial Lung Disease (ILD) or Pulmonary Disease — shares topic coverage
- Antioxidant Activity of Roselle (Hibiscus sabdariffa), Moringa (Moringa oleifera), Ginger (Zingiber officinale) and ‘Ugwu’ (Telfairia occidentalis) in the Lungs of Albino Rats (Rattus norvegicus) Exposed to Cement Dust — shares topic coverage
- A Newborn with Athrogryposis Multiplex Congenital (AMC): A Case Report — shares topic coverage
- LIGHT and FGF-BP are Upregulated in Chronic Liver Injury — shares topic coverage
- Growth Factor Receptors and Liver Injury — shares topic coverage
Article metrics
Real usage data collected on this platform.
0
Page views
0
PDF downloads
0
Outbound clicks
0
Citations
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
No views recorded yet.
Traffic sources
Referring site, by host.
No traffic recorded yet.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.